These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31095683)

  • 1. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
    Gutkind S; Schackman BR; Morgan JR; Leff JA; Agyemang L; Murphy SM; Akiyama MJ; Norton BL; Litwin AH; Linas BP
    Clin Infect Dis; 2020 Mar; 70(7):1397-1405. PubMed ID: 31095683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
    Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
    Schackman BR; Gutkind S; Morgan JR; Leff JA; Behrends CN; Delucchi KL; McKnight C; Perlman DC; Masson CL; Linas BP
    Drug Alcohol Depend; 2018 Apr; 185():411-420. PubMed ID: 29477574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
    Stevens ER; Nucifora KA; Hagan H; Jordan AE; Uyei J; Khan B; Dombrowski K; des Jarlais D; Braithwaite RS
    Clin Infect Dis; 2020 Jun; 70(12):2652-2662. PubMed ID: 31400755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
    Schackman BR; Leff JA; Barter DM; DiLorenzo MA; Feaster DJ; Metsch LR; Freedberg KA; Linas BP
    Addiction; 2015 Jan; 110(1):129-43. PubMed ID: 25291977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.
    Akiyama MJ; Agyemang L; Arnsten JH; Heo M; Norton BL; Schackman BR; Linas BP; Litwin AH
    BMC Infect Dis; 2018 Feb; 18(1):74. PubMed ID: 29426304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: An economic evaluation alongside a pragmatic cluster randomised trial.
    Myring G; Lim AG; Hollingworth W; McLeod H; Beer L; Vickerman P; Hickman M; Radley A; Dillon JF
    J Infect; 2022 Dec; 85(6):676-682. PubMed ID: 36170895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care.
    Norton BL; Akiyama MJ; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Int J Drug Policy; 2021 Jul; 93():103135. PubMed ID: 33667826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
    J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost-effectiveness of Transplanting Hearts From Hepatitis C-infected Donors Into Uninfected Recipients.
    Woolley AE; Gandhi AR; Jones ML; Kim JJ; Mallidi HR; Givertz MM; Baden LR; Mehra MR; Neilan AAM
    Transplantation; 2023 Apr; 107(4):961-969. PubMed ID: 36525554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
    Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
    J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
    J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
    Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
    Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.
    Wei X; Zhao J; Yang L
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33246983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.
    Assoumou SA; Tasillo A; Leff JA; Schackman BR; Drainoni ML; Horsburgh CR; Barry MA; Regis C; Kim AY; Marshall A; Saxena S; Smith PC; Linas BP
    Clin Infect Dis; 2018 Jan; 66(3):376-384. PubMed ID: 29020317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.